Metformin Xr Stada (Metformin Hydrochloride)

Metformin Hydrochloride works primarily by activating AMP‑activated protein kinase (AMPK), which suppresses hepatic glucose production and enhances insulin‑mediated glucose uptake in muscle and fat tissues. This dual action reduces circulating glucose concentrations without stimulating insulin secretion.

The exact dose of Metformin Xr Stada is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and tolerability. Patients should follow the dose prescribed by their clinician.

Safety data for Metformin Xr Stada in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order Metformin Xr Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin Xr Stada belongs to the biguanide class, differing from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors in its mechanism of reducing hepatic glucose output and improving insulin sensitivity. It is generally weight‑neutral and has a low risk of hypoglycaemia when used alone, making it a first‑line option in many treatment guidelines.

Metformin Xr Stada should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Metformin Xr Stada is taken orally, usually once daily with the evening meal to minimise gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not crushed, chewed, or split, as this could affect the extended‑release properties.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with significant renal or hepatic impairment, severe infection, or hypoxia. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, abdominal discomfort, or unusual fatigue develop.

Metformin Xr Stada is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those receiving iodinated contrast studies without adequate renal function monitoring.